(Q36684042)

15 August 2017

1 reference

title

Anti-tumour necrosis factor-alpha therapy in heart failure: future directions (English)

1 reference

15 August 2017

0 references

1 reference

1

Pitchai Balakumar

1 reference

15 August 2017

Manjeet Singh

2

1 reference

15 August 2017

publication date

1 December 2006

1 reference

Basic and Clinical Pharmacology and Toxicology

15 August 2017

published in

1 reference

15 August 2017

volume

99

1 reference

15 August 2017

issue

6

1 reference

15 August 2017

page(s)

391-397

1 reference

Phosphatidic acid signaling mediates lung cytokine expression and lung inflammatory injury after hemorrhage in mice.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Role of cytokines in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Activation of cytokines as a mechanism of disease progression in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Therapeutic strategies to reduce TNF-alpha mediated cardiac contractile depression following ischemia and reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Activation of intrinsic and extrinsic proapoptotic signaling pathways in interleukin-18-mediated human cardiac endothelial cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Cytokines as new treatment targets in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Annexin II is a novel player in insulin signal transduction. Possible association between annexin II phosphorylation and insulin receptor internalization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Tumor necrosis factor in CHF: a double facet cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Role of the NF-kappaB signaling cascade and NF-kappaB-targeted genes in failing human hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Therapeutic inhibition of tumour necrosis factor alpha in patients with heart failure: cooling an inflamed heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Aprotinin is associated with a decrease in nitric oxide production during cardiopulmonary bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Beta blockers in therapy of chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Blockade of NF-kappaB improves cardiac function and survival without affecting inflammation in TNF-alpha-induced cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Case reports of heart failure after therapy with a tumor necrosis factor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Inflammatory mediators and the failing heart: past, present, and the foreseeable future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Differential modulation of cytokine production by drugs: implications for therapy in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Tumour necrosis factor in bronchopulmonary secretions of patients with adult respiratory distress syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Epidemiology of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Effect of a matrix metalloproteinase activity and TNF-alpha converting enzyme inhibitor on intra-abdominal adhesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Tumor necrosis factor-alpha confers resistance to hypoxic injury in the adult mammalian cardiac myocyte.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Tumors secreting human TNF/cachectin induce cachexia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Effects of the stress response in septic rats and LPS-stimulated alveolar macrophages: evidence for TNF-alpha posttranslational regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Biologic rationale for the use of beta-blockers in the treatment of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Tumor necrosis factor-alpha, biologic agents and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Increased nitric oxide in proportion to the severity of heart failure in patients with dilated cardiomyopathy: close correlation of tumor necrosis factor-alpha with systemic and local production of nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

An overview of tumor necrosis factor alpha and the failing human heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Broad modulation of tissue responses (immune activation) by celacade may favorably influence pathologic processes associated with heart failure progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Role of tumour necrosis factor-alpha in the progression of heart failure: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Tumour necrosis factor-alpha and the failing heart--pathophysiology and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Small molecular anti-cytokine agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Inhibition of tumor necrosis factor-alpha-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Recent trends in protein biochip technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

p38 MAP Kinase Mediates Inflammatory Cytokine Induction in Cardiomyocytes and Extracellular Matrix Remodeling in Heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_508.X

10.1111/J.1742-7843.2006.PTO_508.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference